サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1774948

インフルエンザ・ワクチンの世界市場

Influenza Vaccines

出版日
ページ情報
英文 554 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
インフルエンザ・ワクチンの世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 554 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インフルエンザ・ワクチンの世界市場は2030年までに103億米ドルに達する見込み

2024年に74億米ドルと推定されるインフルエンザ・ワクチンの世界市場は、2024年から2030年にかけてCAGR 5.8%で成長し、2030年には103億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである不活化処理は、CAGR 6.8%を記録し、分析期間終了までに74億米ドルに達すると予測されます。弱毒生菌セグメントの成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は20億米ドルと推定、中国はCAGR 9.4％で成長すると予測

米国のインフルエンザ・ワクチン市場は、2024年に20億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と5.8%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界のインフルエンザワクチン市場- 主要動向と促進要因のまとめ

インフルエンザ・ワクチン：進歩、市場動向、世界のインパクト

インフルエンザワクチン市場は、季節性インフルエンザの流行に対する意識の高まりと効果的な予防接種プログラムの必要性により、過去10年間で大きな成長を遂げてきました。世界中の政府やヘルスケア機関は、高齢者、小児、慢性的な健康状態にある人など、リスクの高い人々の入院を減らし、合併症を予防するために、インフルエンザのワクチン接種キャンペーンを優先しています。新型インフルエンザの出現は、ワクチンの定期的な更新と世界のサーベイランス活動の重要性をさらに強調しています。

4価ワクチンや細胞ベースの製剤の開発など、ワクチン技術の進歩により、インフルエンザ・ワクチンの有効性と入手可能性は向上しています。伝統的な卵ベースの製造方法は、現在も広く使用されていますが、組換えDNA技術などの新しいアプローチによって徐々に補完されつつあります。このような技術革新により、製造期間の短縮や株揃えの強化が可能になり、ワクチンの有効性が向上しています。さらに、インフルエンザ予防と他の予防接種を統合した混合ワクチンの台頭が、特に小児医療や老人医療の分野で人気を集めています。

技術革新はどのようにインフルエンザワクチン開発を強化しているのか？

インフルエンザ・ワクチン開発における最も顕著な進歩のひとつは、細胞ベース・ワクチンや遺伝子組換えワクチンへのシフトです。製造に数ヶ月を要し、抗原のドリフトによって有効性が低下する可能性のある卵をベースとしたワクチンとは異なり、細胞をベースとした製造は、より迅速でスケーラブルかつ一貫性のある代替法を提供します。この方法は卵を必要とせず、ワクチンの有効性を損なう突然変異のリスクも低減します。

もうひとつの重要な技術革新は、普遍的なインフルエンザ・ワクチンの開発です。調査チームは、インフルエンザ・ウイルスの保存領域を標的とする広域スペクトラム・ワクチンを研究しており、複数の株に対する長期的な免疫の獲得を目指しています。このアプローチは、毎年のワクチン接種の必要性を減らし、全体的な予防効果を向上させることで、インフルエンザの予防に革命をもたらす可能性があります。万能ワクチンの臨床試験は現在進行中であり、近い将来画期的な進歩を遂げる可能性を示す有望な結果が得られています。

mRNA技術のインフルエンザワクチン製造への統合も、ゲームチェンジャーです。mRNAを用いたCOVID-19ワクチンの成功を受けて、製薬会社は現在、この技術を活用して、より適応性が高く、迅速に展開可能なインフルエンザワクチンを開発しています。

インフルエンザワクチン流通における課題と規制上の留意点とは？

大きな進展にもかかわらず、インフルエンザ・ワクチン市場は、製造の拡張性、流通のロジスティックス、ワクチン接種のためらいに関する課題に直面しています。大きなハードルのひとつは、インフルエンザ・ウイルスの変異が予測不可能であることで、進化する菌株に対応するためには、毎年の再製剤化と大量生産が必要となります。ワクチンの有効性はシーズンによって異なることがあり、社会的信頼とワクチンの普及に課題をもたらしています。

規制当局の承認プロセスも、ワクチンの入手可能性に影響を与えます。インフルエンザ・ワクチンは、配布前に厳格な臨床試験と安全性評価を受けなければならないです。世界保健機関（WHO）や米国食品医薬品局（FDA）を含む世界の保健機関は、菌株の選択、製造方法、流通の枠組みに関するガイドラインを定めています。厳格な安全基準を維持しながら、タイムリーなワクチン展開を確保することは、依然として重要なバランス感覚を必要とします。

もう一つの課題は、特に低所得者や開発途上地域におけるワクチン入手の容易さです。サプライチェーンの制約、冷蔵保存の必要性、流通コストなどが、集団予防接種の妨げとなる可能性があります。恵まれない地域でのインフルエンザワクチンへのアクセスを改善するためには、政府、ワクチン製造業者、非営利団体間の国際協力が不可欠です。WHOの世界のインフルエンザ動向監視・対応システム（GISRS）のような取り組みは、インフルエンザの動向を監視し、ワクチンのタイムリーな更新を促進する上で重要な役割を果たしています。

何がインフルエンザワクチン市場の成長を促進しているのか？

インフルエンザワクチン市場の成長は、ワクチン技術の進歩、予防接種意識の向上、政府主導のワクチン接種プログラムなど、いくつかの要因によって牽引されています。主な要因の1つは、mRNAワクチン、遺伝子組換えワクチン、万能ワクチンなど、有効性の向上と新型株への迅速な適応を実現する次世代インフルエンザワクチンの継続的な開発です。

政府資金や官民パートナーシップの増加も市場拡大に拍車をかけています。多くの国で国家予防接種プログラムが実施され、ワクチン接種率の向上を促すためにワクチン費用が助成されています。インフルエンザの予防接種を行う薬局や小売診療所の役割が増加したことで、特に先進地域ではワクチンへのアクセスがさらに向上しています。

さらに、パンデミックへの備えが世界的に重視されるようになり、インフルエンザ・ワクチン接種の重要性が高まっています。COVID-19パンデミックは、強固な呼吸器疾患予防対策の必要性を浮き彫りにし、インフルエンザワクチンの研究開発への投資拡大につながりました。ヘルスケア制度が予防医療を優先するにつれて、インフルエンザ・ワクチンの需要が高まり、今後数年間の市場の軌道が形成されると予想されます。

セグメント

ワクチンタイプ（不活化,弱毒生）;適応症（4価, 3価）;技術（卵ベース,細胞ベース）;インフルエンザの種類（季節性,パンデミック）;年齢層（小児科,成人）

調査対象企業の例

  • Abbott India Limited
  • AstraZeneca Plc
  • BIKEN Group
  • BioDiem Ltd.
  • CSL Limited
  • CSL Seqirus
  • Daiichi Sankyo Co., Ltd.
  • FluGen, Inc.
  • Gamma Vaccines Pty., Ltd.
  • GlaxoSmithKline plc.

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31618

Global Influenza Vaccines Market to Reach US$10.3 Billion by 2030

The global market for Influenza Vaccines estimated at US$7.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Live attenuated segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 9.4% CAGR

The Influenza Vaccines market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Influenza Vaccine Market - Key Trends & Drivers Summarized

Influenza Vaccines: Advancements, Market Trends, and Global Impact

The influenza vaccine market has seen significant growth over the past decade, driven by increasing awareness of seasonal influenza outbreaks and the need for effective immunization programs. Governments and healthcare organizations worldwide have prioritized flu vaccination campaigns to reduce hospitalizations and prevent complications among high-risk populations, including the elderly, children, and individuals with chronic health conditions. The emergence of new influenza strains has further underscored the importance of regular vaccine updates and global surveillance efforts.

Advancements in vaccine technology, including the development of quadrivalent vaccines and cell-based formulations, have improved the efficacy and availability of influenza vaccines. Traditional egg-based production methods, while still widely used, are gradually being supplemented by newer approaches such as recombinant DNA technology. These innovations allow for faster production timelines and enhanced strain matching, improving vaccine effectiveness. Additionally, the rise of combination vaccines that integrate flu protection with other immunizations is gaining traction, particularly in pediatric and geriatric healthcare sectors.

How Are Technological Innovations Enhancing Influenza Vaccine Development?

One of the most notable advancements in influenza vaccine development is the shift towards cell-based and recombinant vaccines. Unlike egg-based vaccines, which require months to produce and can be less effective due to antigenic drift, cell-based manufacturing offers a faster, more scalable, and consistent alternative. This method eliminates the need for eggs and reduces the risk of mutations that could compromise vaccine effectiveness.

Another key innovation is the development of universal influenza vaccines. Researchers are exploring broad-spectrum vaccines that target conserved regions of the influenza virus, aiming to provide long-term immunity against multiple strains. This approach could revolutionize flu prevention by reducing the need for annual vaccinations and improving overall protection. Clinical trials for universal vaccines are underway, with promising results indicating potential breakthroughs in the near future.

The integration of mRNA technology into influenza vaccine production is also a game-changer. Following the success of mRNA COVID-19 vaccines, pharmaceutical companies are now leveraging this technology to develop more adaptive and rapidly deployable flu vaccines. mRNA-based influenza vaccines could enable real-time strain updates and enhance immune responses, making them a key focus for future immunization strategies.

What Are the Challenges and Regulatory Considerations in Influenza Vaccine Distribution?

Despite significant progress, the influenza vaccine market faces challenges related to production scalability, distribution logistics, and vaccine hesitancy. One major hurdle is the unpredictability of influenza virus mutations, requiring annual reformulation and mass production to keep up with evolving strains. The effectiveness of vaccines can vary from season to season, creating challenges in public confidence and vaccine adoption.

Regulatory approval processes also impact vaccine availability. Influenza vaccines must undergo rigorous clinical trials and safety evaluations before they can be distributed. Global health agencies, including the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA), establish guidelines for strain selection, manufacturing practices, and distribution frameworks. Ensuring timely vaccine rollout while maintaining stringent safety standards remains a critical balancing act.

Another challenge is vaccine accessibility, particularly in low-income and developing regions. Supply chain limitations, cold storage requirements, and distribution costs can hinder mass immunization efforts. International collaborations between governments, vaccine manufacturers, and non-profit organizations are essential to improving access to flu vaccines in underprivileged areas. Efforts such as the WHO’s Global Influenza Surveillance and Response System (GISRS) play a crucial role in monitoring flu trends and facilitating timely vaccine updates.

What Is Driving the Growth of the Influenza Vaccine Market?

The growth in the influenza vaccine market is driven by several factors, including advancements in vaccine technology, increasing immunization awareness, and government-led vaccination programs. One of the primary drivers is the continuous development of next-generation flu vaccines, including mRNA, recombinant, and universal vaccines, which offer improved efficacy and faster adaptability to emerging strains.

The rise in government funding and public-private partnerships has also fueled market expansion. Many countries have implemented national immunization programs and subsidized vaccine costs to encourage higher vaccination rates. The increasing role of pharmacies and retail clinics in administering flu shots has further improved vaccine accessibility, particularly in developed regions.

Additionally, the growing global focus on pandemic preparedness has reinforced the importance of influenza vaccination. The COVID-19 pandemic has highlighted the need for robust respiratory disease prevention measures, leading to increased investments in flu vaccine research and development. As healthcare systems prioritize preventive care, the demand for influenza vaccines is expected to rise, shaping the market’s trajectory in the coming years.

SCOPE OF STUDY:

The report analyzes the Influenza Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Inactivated, Live attenuated); Indication (Quadrivalent, Trivalent); Technology (Egg-based, Cell-based); Flu Type (Seasonal, Pandemic); Age Group (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott India Limited
  • AstraZeneca Plc
  • BIKEN Group
  • BioDiem Ltd.
  • CSL Limited
  • CSL Seqirus
  • Daiichi Sankyo Co., Ltd.
  • FluGen, Inc.
  • Gamma Vaccines Pty., Ltd.
  • GlaxoSmithKline plc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Influenza Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Global Focus on Pandemic Preparedness and Seasonal Immunization Drives Vaccine Uptake
    • Expansion of National Immunization Programs and Free Vaccine Initiatives Spurs Market Penetration
    • Rising Demand for Quadrivalent and Cell-Based Vaccines Strengthens Business Case for Next-Gen Formulations
    • Aging Population and High-Risk Group Vulnerability Accelerates Demand for Annual Influenza Vaccination
    • Technological Advancements in mRNA and Recombinant Platforms Open New Pathways for Flu Vaccine Innovation
    • Public Health Campaigns and Awareness Programs Boost Seasonal Vaccination Compliance Rates
    • Emerging Markets Strengthen Healthcare Infrastructure to Improve Influenza Vaccine Accessibility
    • Regulatory Support for Fast-Track Approvals and Strain Updates Enables Rapid Commercialization
    • Partnerships Between Vaccine Manufacturers and Governments Enhance Strategic Stockpiling and Distribution
    • Growing Concern Over Zoonotic and Mutated Influenza Strains Fuels Long-Term R&D Investment
    • Expansion of Retail Pharmacies and Digital Scheduling Improves Vaccine Availability and Convenience
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Influenza Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Live attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Quadrivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Quadrivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Quadrivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Trivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Egg-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Egg-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Egg-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cell-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cell-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cell-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Seasonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Seasonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Seasonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pandemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pandemic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Pandemic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • JAPAN
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • CHINA
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • EUROPE
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Influenza Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • FRANCE
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 113: France Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • GERMANY
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Germany 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Italy 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Italy 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 158: UK Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: UK 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: UK 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: UK 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: UK 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Spain 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Spain 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Spain 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Spain 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Spain 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Russia 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Russia 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Russia 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Russia 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 200: Russia Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Russia Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Russia 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Europe 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Europe Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Europe 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Europe Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Europe Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Europe 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Influenza Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 227: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Asia-Pacific Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 230: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Asia-Pacific Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Asia-Pacific Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Asia-Pacific 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Australia 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 239: Australia Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Australia Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Australia 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 242: Australia Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Australia Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Australia 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 245: Australia Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Australia Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Australia 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 248: Australia Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Australia Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Australia 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • INDIA
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 251: India Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: India Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: India 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 254: India Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: India Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: India 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 257: India Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: India Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: India 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 260: India Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: India Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: India 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 263: India Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: India Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: India 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 266: South Korea Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: South Korea Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: South Korea 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 269: South Korea Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: South Korea Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: South Korea 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 272: South Korea Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: South Korea Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: South Korea 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 275: South Korea Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: South Korea Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: South Korea 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 278: South Korea Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: South Korea Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: South Korea 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 281: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Asia-Pacific Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Asia-Pacific 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Asia-Pacific Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Asia-Pacific 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Asia-Pacific Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Asia-Pacific 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Asia-Pacific Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Asia-Pacific 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Asia-Pacific Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Asia-Pacific 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 296: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 297: Latin America Historic Review for Influenza Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Latin America 15-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 299: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Latin America Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Latin America 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 302: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Latin America Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Latin America 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 305: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Latin America Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Latin America 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 308: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Latin America Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Latin America 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 311: Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Latin America Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Latin America 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 314: Argentina Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Argentina Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Argentina 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 317: Argentina Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Argentina Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Argentina 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 320: Argentina Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Argentina Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Argentina 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 323: Argentina Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Argentina Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Argentina 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 326: Argentina Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Argentina Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Argentina 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 329: Brazil Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Brazil Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Brazil 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 332: Brazil Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Brazil Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Brazil 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 335: Brazil Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Brazil Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Brazil 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 338: Brazil Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Brazil Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Brazil 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 341: Brazil Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Brazil Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Brazil 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 344: Mexico Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Mexico Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Mexico 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 347: Mexico Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Mexico Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Mexico 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 350: Mexico Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Mexico Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Mexico 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 353: Mexico Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Mexico Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Mexico 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 356: Mexico Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Mexico Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Mexico 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 359: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Rest of Latin America Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Rest of Latin America 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 362: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Rest of Latin America Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Rest of Latin America 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 365: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Rest of Latin America Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Rest of Latin America 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 368: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Rest of Latin America Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Rest of Latin America 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 371: Rest of Latin America Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Latin America Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Latin America 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 374: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 375: Middle East Historic Review for Influenza Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Middle East 15-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 377: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Middle East Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Middle East 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 380: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Middle East Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Middle East 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 383: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Middle East Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Middle East 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 386: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Middle East Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Middle East 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 389: Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Middle East Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Middle East 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 392: Iran Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Iran Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Iran 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 395: Iran Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Iran Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Iran 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 398: Iran Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Iran Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Iran 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 401: Iran Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Iran Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Iran 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 404: Iran Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Iran Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Iran 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 407: Israel Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Israel Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Israel 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 410: Israel Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Israel Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Israel 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 413: Israel Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Israel Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Israel 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 416: Israel Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Israel Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Israel 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 419: Israel Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Israel Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Israel 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 422: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Saudi Arabia Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 424: Saudi Arabia 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 425: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Saudi Arabia Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 427: Saudi Arabia 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 428: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Saudi Arabia Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 430: Saudi Arabia 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 431: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Saudi Arabia Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 433: Saudi Arabia 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 434: Saudi Arabia Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Saudi Arabia Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 436: Saudi Arabia 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 437: UAE Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 438: UAE Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 439: UAE 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 440: UAE Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 441: UAE Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 442: UAE 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 443: UAE Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 444: UAE Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 445: UAE 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 446: UAE Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 447: UAE Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 448: UAE 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 449: UAE Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 450: UAE Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 451: UAE 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 452: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 453: Rest of Middle East Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 454: Rest of Middle East 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 455: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 456: Rest of Middle East Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 457: Rest of Middle East 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 458: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 459: Rest of Middle East Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 460: Rest of Middle East 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 461: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 462: Rest of Middle East Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 463: Rest of Middle East 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 464: Rest of Middle East Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 465: Rest of Middle East Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 466: Rest of Middle East 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030
  • AFRICA
    • Influenza Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 467: Africa Recent Past, Current & Future Analysis for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 468: Africa Historic Review for Influenza Vaccines by Vaccine Type - Inactivated and Live attenuated Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 469: Africa 15-Year Perspective for Influenza Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Inactivated and Live attenuated for the Years 2015, 2025 & 2030
    • TABLE 470: Africa Recent Past, Current & Future Analysis for Influenza Vaccines by Age Group - Adults and Pediatrics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Africa Historic Review for Influenza Vaccines by Age Group - Adults and Pediatrics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 472: Africa 15-Year Perspective for Influenza Vaccines by Age Group - Percentage Breakdown of Value Sales for Adults and Pediatrics for the Years 2015, 2025 & 2030
    • TABLE 473: Africa Recent Past, Current & Future Analysis for Influenza Vaccines by Indication - Quadrivalent and Trivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Africa Historic Review for Influenza Vaccines by Indication - Quadrivalent and Trivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 475: Africa 15-Year Perspective for Influenza Vaccines by Indication - Percentage Breakdown of Value Sales for Quadrivalent and Trivalent for the Years 2015, 2025 & 2030
    • TABLE 476: Africa Recent Past, Current & Future Analysis for Influenza Vaccines by Technology - Egg-based and Cell-based - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Africa Historic Review for Influenza Vaccines by Technology - Egg-based and Cell-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 478: Africa 15-Year Perspective for Influenza Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based and Cell-based for the Years 2015, 2025 & 2030
    • TABLE 479: Africa Recent Past, Current & Future Analysis for Influenza Vaccines by Flu Type - Seasonal and Pandemic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Africa Historic Review for Influenza Vaccines by Flu Type - Seasonal and Pandemic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 481: Africa 15-Year Perspective for Influenza Vaccines by Flu Type - Percentage Breakdown of Value Sales for Seasonal and Pandemic for the Years 2015, 2025 & 2030

IV. COMPETITION